Table 3.
Correlation of combinatorial CAIX/HIF-1α tumour cell expression with survival outcomes in patients with TNBC
| Unadjusted | Adjusteda | |||||||
|---|---|---|---|---|---|---|---|---|
| No of events | No of patients | HR (95% CI) |
P value | No of events | No of patients | HR (95% CI) | P value | |
| Disease-free survival (DFS) | ||||||||
| HIF-1α and CAIX | ||||||||
| HIF-1α negative & CAIX negative | 20 | 98 | Reference | 15 | 74 | Reference | ||
| HIF-1α negative & CAIX positive | 18 | 46 |
2.48 (1.31,4.69) |
0.0053* | 17 | 39 |
2.66 (1.3, 5.45) |
0.0076* |
| HIF-1α positive & CAIX negative | 15 | 66 |
1.08 (0.55,2.1) |
0.8273 | 14 | 49 |
1.48 (0.7, 3.1) |
0.3012 |
| HIF-1α positive & CAIX positive | 27 | 58 |
3.07 (1.72,5.49) |
0.0002* | 24 | 45 |
4.46 (2.26, 8.81) |
< 0.0001* |
| Overall-survival (OS) | ||||||||
| HIF-1α and CAIX | ||||||||
| HIF-1α negative & CAIX negative | 19 | 98 | Reference | 15 | 74 | Reference | ||
| HIF-1α negative & CAIX positive | 14 | 46 |
1.99 (1, 3.97) |
0.0513 | 13 | 39 |
1.74 (0.8, 3.8) |
0.1636 |
| HIF-1α positive & CAIX negative | 11 | 66 |
0.8 (0.38, 1.69) |
0.5657 | 10 | 49 |
0.94 (0.4, 2.19) |
0.8844 |
| HIF-1α positive & CAIX positive | 18 | 57 |
2.3 (1.2, 4.39) |
0.0119* | 16 | 44 |
3.3 (1.57, 6.94) |
0.0016* |
aMultivariate analysis was adjusted for age, grade, tumour size and lymph node stage
*Statistically significant values (P < 0.05)